HSP
Heat shock proteins
HSP (Heat shock proteins) are a group of proteins induced by heat shock, the most prominent members of this group are a class of functionally related proteins involved in the folding and unfolding of other proteins. HSP expression is increased when cells are exposed to elevated temperatures or other stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins appear to serve a significant cardiovascular role. Hsp90, Hsp84, Hsp70, Hsp27, Hsp20 and alpha B crystallin all have been reported as having roles in the cardiovasculature.
HSP Isoform Specific Products
All Product Categories
-
HSP Inhibitors
(324)
View all products
-
HSP Agonists
(2)
View all products
-
HSP Antagonists
(5)
View all products
-
HSP Activators
(88)
View all products
-
HSP Modulators
(6)
View all products
-
HSP Inducers
(7)
View all products
-
HSP Degraders
(7)
View all products
-
HSP Pre-designed Set
(1)
View all products
-
HSP Controls
(2)
View all products
-
HSP Ligands
(11)
View all products
-
HSP Related Products (503)
Related Products (503)
-
Antibodies (46)
-
HSP Isoform Comparison
-
Hsp90-IN-17
0 ImagesCat. No.: HY-148215CAS No.: 1253584-78-9Hsp90-IN-17 is a Hsp90 inhibitor. Hsp90-IN-17 binds to the N-terminal ATP-binding pocket of Hsp90, inhibits its chaperone function, and induces the degradation of Hsp90 client proteins. Hsp90-IN-17 inhibits cancer cell proliferation. Hsp90-IN-17 can be used in the research of ovarian cancer.
-
Aminohexylgeldanamycin hydrochloride
0 ImagesCat. No.: HY-133571ACAS No.: 1146534-45-3Synonyms: AHGDM hydrochlorideAminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities.
-
Dehydroherbarin
0 ImagesCat. No.: HY-N9722CAS No.: 36379-74-5Dehydroherbarin is a selective inhibitor targeting HSP90α with blood-brain barrier penetration. Dehydroherbarin interferes with key pathways of tumor cell survival by binding to HSP90α, while exerting moderate antibacterial and anti-hepatitis A virus activities and inhibiting tumor cell migration. Dehydroherbarin can be used in research on tumors such as breast cancer.
-
NN-01-195
0 ImagesCat. No.: HY-181626NN-01-195 is a HSP90 and AURKA inhibitor. NN-01-195 binds tightly to and inhibits AURKA and HSP90, with an IC50 of 3.1 nM against AURKA and an IC50 of 8.7 nM against HSP90α. NN-01-195 induces mitotic arrest and spindle abnormality in tumor cells, and triggers cell apoptosis. NN-01-195 can be used in the research of solid tumors.
-
YM-08
0 ImagesCat. No.: HY-139144CAS No.: 812647-88-4
-
HDAC/HSP90-IN-1
0 ImagesCat. No.: HY-130273CAS No.: 2244714-37-0HDAC/HSP90-IN-1 (compound 20) is a potent dual inhibitor of HDAC (IC50 = 194 nM) and HSP90 (HSP90α IC50 = 153 nM). HDAC/HSP90-IN-1 induces HSP70 expression, downregulates HSP90 client proteins, and promotes acetylation of α-tubulin and histone H3 in cancer cells. HDAC/HSP90-IN-1 reduces PD-L1 expression in IFN-γ treated H1975 cells. HDAC/HSP90-IN-1 can be used for cancer research, such as lung and colon cancer.
-
PU-H39
0 ImagesCat. No.: HY-121723CAS No.: 852030-38-7PU-H39 is a selective Grp94 inhibitor with an IC50 of 0.12 μM. PU-H39 can be used for the research of breast cancer.
-
DMT003096
0 ImagesCat. No.: HY-12619CAS No.: 912361-26-3DMT003096 is an Hsp70 inhibitor that inhibits J domain (TAg)-stimulated Hsp70 ATPase activity without affecting endogenous Hsp70 ATP hydrolysis.DMT003096 inhibits breast cancer cell proliferation.DMT003096 can be used for the research of breast cancer.
-
Hsp90-IN-40
0 ImagesCat. No.: HY-171755CAS No.: 2169278-81-1Hsp90-IN-40 (Compound 15b) is a heat shock protein 90 (Hsp90) C-terminal inhibitor. Hsp90-IN-40 exhibits antiproliferative activity against SKBr3 and MCF-7 breast cancer cells (IC50 of 2.57 µM and 2.43 µM, respectively). Hsp90-IN-40 inhibits cancer cell growth by inhibiting the Hsp90 C-terminal function, leading to Hsp90-dependent protein degradation. Hsp90-IN-40 can be used in breast cancer research.
-
Hsp90-IN-47
0 ImagesCat. No.: HY-186076CAS No.: 958888-13-6Hsp90-IN-47 (Compound C15) is a Hsp90 inhibitor and antifungal agent, with an IC50 of 0.014 μM against Hsp90α. When combined with Fluconazole (HY-B0101), Hsp90-IN-47 exerts significant synergistic antifungal effects against fluconazole-resistant Candida albicans 0304103. Hsp90-IN-47 exhibits antitumor activity against acute myeloid leukemia and non-small cell lung cancer.
-
STA-1474
0 ImagesCat. No.: HY-13752CAS No.: 1118915-78-8STA-1474 is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 can be used in the research of osteosarcoma.
-
(Rac)-Zearalanone-d6
0 ImagesCat. No.: HY-N6678SCAS No.: 1795020-90-4(Rac)-Zearalanone-d6 is the d6-labeled (Rac)-Zearalanone (HY-N6678A). (Rac)-Zearalanone is an ATP-competitive HSP90 inhibitor with an EC50 of 2.3 μM. (Rac)-Zearalanone interferes with the binding of ATP to HSP90, impairs the chaperone function of HSP90, and promotes the degradation of client proteins. (Rac)-Zearalanone reduces intracellular accumulation of Raf-1, induces cleavage of caspase-3, and promotes Her2 degradation in a dose-dependent manner by disrupting the Her2-HSP90 interaction. (Rac)-Zearalanone can be used in the research of small cell lung cancer and breast cancer.
-
Hsp90-IN-15
0 ImagesCat. No.: HY-150655CAS No.: 2252283-32-0Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell.
-
Antiproliferative agent-72
0 ImagesCat. No.: HY-176538CAS No.: 1052646-54-4Antiproliferative agent-72 (Compound 10) is a Hsp90 inhibitor with a Kd of 11 nM. Antiproliferative agent-72 has antiproliferative activity with IC50s of 1.5 μM and 1.1 μM for HCT116 and NCI-N87 cells, respectively. Antiproliferative agent-72 can be used for cancers research.
-
Hsp90-Cdc37-IN-4
0 ImagesCat. No.: HY-174347CAS No.: 2758818-41-4Hsp90-Cdc37-IN-4, a Celastrol (HY-13067) derivative, inhibits the Hsp90-Cdc37 protein-protein interaction (PPI). Hsp90-Cdc37-IN-4 selectively inhibits casein kinase 2 (CK2), reducing phosphorylation of its substrate Cdc37 at Serine 13. Hsp90-Cdc37-IN-4 induces G0/G1 cell cycle arrest and triggers apoptosis via the mitochondrial pathway. Hsp90-Cdc37-IN-4 demonstrates potent anti-breast cancer activity.
-
Hsp90-IN-38
0 ImagesCat. No.: HY-170895CAS No.: 3065556-04-6Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong HSP90 binding affinity with a Kd of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC50 of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC50s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively.
-
PU-20F
0 ImagesCat. No.: HY-121706CAS No.: 422508-29-0PU-20F is a Hsp90 inhibitor with an EC50 of 6.8 μM. PU-20F competes with Geldanamycin (HY-15230) for binding to Hsp90 and regulates the function of this molecular chaperone. PU-20F induces the degradation of oncogenic Her2 tyrosine kinase. PU-20F blocks the growth of breast cancer cells. PU-20F can be used in breast cancer-related research.
